Today’s Market Runner: What’s Ahead for InVitae Corp After Today’s Huge Decline?

Today's Market Runner: What's Ahead for InVitae Corp After Today's Huge Decline?

The stock of InVitae Corp (NYSE:NVTA) is a huge mover today! About 618,154 shares traded hands or 423.54% up from the average. InVitae Corp (NYSE:NVTA) has declined 20.21% since April 14, 2016 and is downtrending. It has underperformed by 24.89% the S&P500.
The move comes after 6 months negative chart setup for the $224.75 million company. It was reported on Nov, 16 by Barchart.com. We have $6.30 PT which if reached, will make NYSE:NVTA worth $22.48 million less.

InVitae Corp (NYSE:NVTA) Ratings Coverage

Out of 3 analysts covering Invitae (NYSE:NVTA), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Invitae has been the topic of 4 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The firm has “Mkt Perform” rating by William Blair given on Friday, August 14. Leerink Swann downgraded the shares of NVTA in a report on Thursday, January 28 to “Mkt Perform” rating. Leerink Swann reinitiated InVitae Corp (NYSE:NVTA) on Thursday, November 10 with “Outperform” rating. The firm has “Overweight” rating given on Tuesday, August 9 by JP Morgan.

According to Zacks Investment Research, “Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.”

More recent InVitae Corp (NYSE:NVTA) news were published by: Reuters.com which released: “BRIEF-Invitae corp – has commenced an underwritten public offering of $40 …” on November 15, 2016. Also Reuters.com published the news titled: “BRIEF-Invitae Corp entered into a provider agreement for laboratory servic…” on September 13, 2016. Bizjournals.com‘s news article titled: “EXCLUSIVE: DNA testing giant leases entire Potrero Hill redevelopment site” with publication date: September 22, 2015 was also an interesting one.

NVTA Company Profile

Invitae Corporation (Invitae), incorporated on January 13, 2010, utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment